Kim Sung-Wan, Shin Il-Seon, Kim Jae-Min, Lee Seung-Hyun, Lee Yo-Han, Yang Su-Jin, Yoon Jin-Sang
Department of Psychiatry, Chonnam National University Medical School and Clinical Trial Center, Chonnam National University Hospital, Gwangju, Republic of Korea.
Hum Psychopharmacol. 2009 Oct;24(7):565-73. doi: 10.1002/hup.1057.
To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable risperidone (LAIR) in patients with schizophrenia.
Thirty-six patients with schizophrenia treated with oral AAPs participated in this open-label, 26-week study. Cognitive functions were measured at baseline and at 12 and 26 weeks. The secondary outcome measures included the Positive and Negative Syndrome Scale (PANSS), Social and Occupational Functioning Assessment Scale (SOFAS), Scale for Unawareness of Mental Disorder (SUMD), and measurements for extrapyramidal symptoms.
Significant improvements in cognitive function were observed in the backward Digit Span Test, Verbal Learning Test, Wisconsin Card Sorting Test, correct responses on the Continuous Performance Test, and Trail Making Test part B following a switch to LAIR. Scores on the PANSS, SOFAS, SUMD, and the Simpson-Angus Rating Scale also improved significantly. Most improvements in neurocognitive function were not correlated with clinical measures. Weight gain and hyperprolactinemia were the most common adverse events.
Switching from oral AAPs to LAIR improved cognitive function including vigilance, verbal learning and memory, executive function, sustained attention, and visuomotor speed in patients with schizophrenia. It was also effective for improving psychotic symptoms, social functioning, and insight.
探讨精神分裂症患者从口服非典型抗精神病药物（AAPs）换用长效注射利培酮（LAIR）后认知功能和临床特征的变化。
36例接受口服AAPs治疗的精神分裂症患者参与了这项开放标签的26周研究。在基线、第12周和第26周测量认知功能。次要结局指标包括阳性和阴性症状量表（PANSS）、社会和职业功能评估量表（SOFAS）、精神障碍自知力量表（SUMD）以及锥体外系症状测量。
换用LAIR后，在数字广度倒背测验、言语学习测验、威斯康星卡片分类测验、连续性能测验正确反应数以及连线测验B部分中，认知功能有显著改善。PANSS、SOFAS、SUMD和辛普森 - 安格斯评定量表的得分也显著改善。神经认知功能的大多数改善与临床指标无关。体重增加和高催乳素血症是最常见的不良事件。
精神分裂症患者从口服AAPs换用LAIR可改善认知功能，包括警觉性、言语学习和记忆、执行功能、持续注意力以及视觉运动速度。对改善精神病性症状、社会功能和自知力也有效。
